Healthy
Conditions
Brief summary
The purpose of this study is to assess the effect of multiple dose administrations of Omeprazole on the pharmacokinetics of BMS-986205.
Interventions
DRUGBMS-986205
Participants will receive BMS-986205 on Days 1 and 15
DRUGomeprazole
Participants will receive omeprazole on Days 10 to 15
Sponsors
Bristol-Myers Squibb
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Health male and female participants (not of childbearing potential) as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations * normal renal function at screening as evidenced by an estimated glomerular filtration rate (GFR) greater than or equal to (\>=) 80 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) * Body mass index (BMI) of 18.0 kilogram per meter square (kg/m\^2) to 32.0 kg/m\^2 * Women participants must have documented proof that they are not of childbearing potential
Exclusion criteria
* Women who are of childbearing potential or breastfeeding * Active tuberculosis (TB) requiring treatment or documented latent TB within the previous 3 years * Concomitant use of strong inhibitors or strong inducers of CYP3A4 * Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of BMS-986205 | Up to Day 29 |
| Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration [AUC(0-T)] of BMS-986205 | Up to Day 29 |
| Area Under the Plasma Concentration-time Curve from Time Zero Extrapolated to Infinite Time [AUC(INF)] | Up to Day 29 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Physical Examination Abnormalities | Up to Day 29 |
| Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Discontinuation | Up to Day 36 |
| Number of Participants with Clinical Laboratory Results Abnormalities | Up to Day 29 |
| Number of Participants with Vital Sign Abnormalities | Up to Day 29 |
| Number of Participants with 12-lead Electrocardiogram (ECG) Abnormalities | Up to Day 29 |
Countries
United States
Outcome results
None listed